These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

190 related articles for article (PubMed ID: 15625606)

  • 1. Comparison of antigen constructs and carrier molecules for augmenting the immunogenicity of the monosaccharide epithelial cancer antigen Tn.
    Kagan E; Ragupathi G; Yi SS; Reis CA; Gildersleeve J; Kahne D; Clausen H; Danishefsky SJ; Livingston PO
    Cancer Immunol Immunother; 2005 May; 54(5):424-30. PubMed ID: 15625606
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A preclinical study comparing approaches for augmenting the immunogenicity of a heptavalent KLH-conjugate vaccine against epithelial cancers.
    Ragupathi G; Koide F; Sathyan N; Kagan E; Spassova M; Bornmann W; Gregor P; Reis CA; Clausen H; Danishefsky SJ; Livingston PO
    Cancer Immunol Immunother; 2003 Oct; 52(10):608-16. PubMed ID: 12811527
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Vaccines prepared with sialyl-Tn and sialyl-Tn trimers using the 4-(4-maleimidomethyl)cyclohexane-1-carboxyl hydrazide linker group result in optimal antibody titers against ovine submaxillary mucin and sialyl-Tn-positive tumor cells.
    Ragupathi G; Howard L; Cappello S; Koganty RR; Qiu D; Longenecker BM; Reddish MA; Lloyd KO; Livingston PO
    Cancer Immunol Immunother; 1999 Apr; 48(1):1-8. PubMed ID: 10235483
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparison of the effect of different immunological adjuvants on the antibody and T-cell response to immunization with MUC1-KLH and GD3-KLH conjugate cancer vaccines.
    Kim SK; Ragupathi G; Musselli C; Choi SJ; Park YS; Livingston PO
    Vaccine; 1999 Nov; 18(7-8):597-603. PubMed ID: 10547417
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparison of antibody titers after immunization with monovalent or tetravalent KLH conjugate vaccines.
    Ragupathi G; Cappello S; Yi SS; Canter D; Spassova M; Bornmann WG; Danishefsky SJ; Livingston PO
    Vaccine; 2002 Jan; 20(7-8):1030-8. PubMed ID: 11803062
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effect of immunological adjuvant combinations on the antibody and T-cell response to vaccination with MUC1-KLH and GD3-KLH conjugates.
    Kim SK; Ragupathi G; Cappello S; Kagan E; Livingston PO
    Vaccine; 2000 Oct; 19(4-5):530-7. PubMed ID: 11027818
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Immunogenicity of synthetic TF-KLH (keyhole limpet hemocyanin) and sTn-KLH conjugates in colorectal carcinoma patients.
    Adluri S; Helling F; Ogata S; Zhang S; Itzkowitz SH; Lloyd KO; Livingston PO
    Cancer Immunol Immunother; 1995 Sep; 41(3):185-92. PubMed ID: 7553688
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Identification of DHBcAg as a potent carrier protein comparable to KLH for augmenting MUC1 antigenicity.
    Gathuru JK; Koide F; Ragupathi G; Adams JL; Kerns RT; Coleman TP; Livingston PO
    Vaccine; 2005 Sep; 23(39):4727-33. PubMed ID: 15978705
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Fully synthetic carbohydrate-based vaccines in biochemically relapsed prostate cancer: clinical trial results with alpha-N-acetylgalactosamine-O-serine/threonine conjugate vaccine.
    Slovin SF; Ragupathi G; Musselli C; Olkiewicz K; Verbel D; Kuduk SD; Schwarz JB; Sames D; Danishefsky S; Livingston PO; Scher HI
    J Clin Oncol; 2003 Dec; 21(23):4292-8. PubMed ID: 14645418
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Keyhole limpet hemocyanin conjugate vaccines against cancer: the Memorial Sloan Kettering experience.
    Musselli C; Livingston PO; Ragupathi G
    J Cancer Res Clin Oncol; 2001 Oct; 127 Suppl 2():R20-6. PubMed ID: 11768620
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Thomsen-Friedenreich (TF) antigen as a target for prostate cancer vaccine: clinical trial results with TF cluster (c)-KLH plus QS21 conjugate vaccine in patients with biochemically relapsed prostate cancer.
    Slovin SF; Ragupathi G; Musselli C; Fernandez C; Diani M; Verbel D; Danishefsky S; Livingston P; Scher HI
    Cancer Immunol Immunother; 2005 Jul; 54(7):694-702. PubMed ID: 15726361
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Synthesis of sialyl Lewis(a) (sLe (a), CA19-9) and construction of an immunogenic sLe(a) vaccine.
    Ragupathi G; Damani P; Srivastava G; Srivastava O; Sucheck SJ; Ichikawa Y; Livingston PO
    Cancer Immunol Immunother; 2009 Sep; 58(9):1397-405. PubMed ID: 19190907
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Synthesis and immunological evaluation of a MUC1 glycopeptide incorporated into l-rhamnose displaying liposomes.
    Sarkar S; Salyer AC; Wall KA; Sucheck SJ
    Bioconjug Chem; 2013 Mar; 24(3):363-75. PubMed ID: 23444835
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Chemoenzymatically synthesized multimeric Tn/STn MUC1 glycopeptides elicit cancer-specific anti-MUC1 antibody responses and override tolerance.
    Sørensen AL; Reis CA; Tarp MA; Mandel U; Ramachandran K; Sankaranarayanan V; Schwientek T; Graham R; Taylor-Papadimitriou J; Hollingsworth MA; Burchell J; Clausen H
    Glycobiology; 2006 Feb; 16(2):96-107. PubMed ID: 16207894
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Augmenting the immunogenicity of synthetic MUC1 peptide vaccines in mice.
    Zhang S; Graeber LA; Helling F; Ragupathi G; Adluri S; Lloyd KO; Livingston PO
    Cancer Res; 1996 Jul; 56(14):3315-9. PubMed ID: 8764127
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Specificity of the IgG response in mice and human breast cancer patients following immunization against synthetic sialyl-Tn, an epitope with possible functional significance in metastasis.
    Longenecker BM; Reddish M; Koganty R; MacLean GD
    Adv Exp Med Biol; 1994; 353():105-24. PubMed ID: 7527178
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Constructing an adenocarcinoma vaccine: immunization of mice with synthetic KH-1 nonasaccharide stimulates anti-KH-1 and anti-Le(y) antibodies.
    Ragupathi G; Deshpande PP; Coltart DM; Kim HM; Williams LJ; Danishefsky SJ; Livingston PO
    Int J Cancer; 2002 May; 99(2):207-12. PubMed ID: 11979435
    [TBL] [Abstract][Full Text] [Related]  

  • 18. From synthesis to biologics: preclinical data on a chemistry derived anticancer vaccine.
    Zhu J; Wan Q; Lee D; Yang G; Spassova MK; Ouerfelli O; Ragupathi G; Damani P; Livingston PO; Danishefsky SJ
    J Am Chem Soc; 2009 Jul; 131(26):9298-303. PubMed ID: 19518111
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Synthesis and immunological evaluation of MUC1 glycopeptide conjugates bearing N-acetyl modified STn derivatives as anticancer vaccines.
    Xiao A; Zheng XJ; Song C; Gui Y; Huo CX; Ye XS
    Org Biomol Chem; 2016 Jul; 14(30):7226-37. PubMed ID: 27380866
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Antibodies against mucin-associated sialyl-Tn epitopes correlate with survival of metastatic adenocarcinoma patients undergoing active specific immunotherapy with synthetic STn vaccine.
    MacLean GD; Reddish MA; Koganty RR; Longenecker BM
    J Immunother Emphasis Tumor Immunol; 1996 Jan; 19(1):59-68. PubMed ID: 8859725
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.